1.
Space reserved for the
image of the speaker
Nuevas fronteras en la reducción del riesgo CV
residual.
Nuevos datos clínicos con icosapento de etilo
Dr. Vivencio Barrios Alonso
Hospital Universitario Ramón y Cajal, Madrid

2.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
Conflictos de Interés
Ponente/consultor para:
Abbott; Amarin; AstraZeneca; Bayer Schering Pharma; Boehringer Ingelheim
Pharmaceuticals GmbH; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Ferrer
International SA; Menarini Group Farma; Novartis AG; Pfizer; Recordati Pharma; Roche
Pharma; Sanofi-Aventis; Servier Laboratories; Takeda Pharmaceuticals GmbH

3.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
REDUCE-IT
Trial Design

4.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
REDUCE-IT
Main Results
NNT in Secondary Prevention: 14

5.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
Safety Profile

6.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
Safety Profile

7.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
REDUCE-IT
Conclusion

8.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
Number needed to treat to avoid 1 episode in
patients with high cardiovascular risk

9.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
Summary of REDUCE-IT
Subgroup Analyses

10.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
Primary Endpoint Events by
eGFR at Baseline

11.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
Cardiovascular Benefits of Icosapent Ethyl in Patients
With Diabetes: REDUCE-IT Diabetes

12.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
Time to Elective, Urgent and Emergent
Revascularisation Events

13.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
Cardiac Arrest and Sudden Cardiac Death
in Patients With Prior MI

14.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
Icosapent Ethyl
Reduced First and Total Strokes

15.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
RESPECT - Trial Scheme

16.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
Primary and Secondary Endpoints

17.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
Safety Outcomes

18.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
Post-hoc Analysis (Primary Endpoint)

19.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker

20.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
Consensus Statement From the Spanish Society of
Cardiology and the Spanish Society of Diabetes

21.
Vivencio Barrios Alonso
Nuevos datos clínicos con icosapento de etilo
Space reserved for the
image of the speaker
https://www.nice.org.uk/guidance/ta805/documents/final-appraisal-determination-document
Icosapent ethyl demonstrates cost-effectiveness in secondary prevention: at a price
that in euros would be approximately €170, the incremental cost-effectiveness ratio (ICER) is
between £21,750 and £24,821 per QALY (quality-adjusted life years of life)
Cost-Effectiveness Studies